---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-040523"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:07:38.587629+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oragenics updates on concussion drug ONP-002 progress; Phase II trial preparation advanced

## Summary
- ONP-002 cleared FDA cardiotoxicity and genotoxicity tests; spray-dry formulation completed with 4-fold drug increase per dose.
- $4.45M public offering closed Sep 2024; total $6M+ raised in 2024 to fund Phase II trial.
- Phase II trial planned later 2024, first in Australia then U.S.; evaluates efficacy on symptom reduction and functional recovery.
- Appointed Dr. James Kelly as CMO and Dr. William Peacock as CCO in 2024 for clinical oversight.
- Partnership with Avance Clinical in May 2024; Australian Regulatory Submission Brochure targeted Q4 2024.

## SEC filing metadata
- accession: 0001493152-24-040523
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315224040523/0001493152-24-040523-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315224040523/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-040523
- JSON: https://secwatch.observer/filing/0001493152-24-040523.json
- Plain text: https://secwatch.observer/filing/0001493152-24-040523.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.